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rotected Carotid Stenting in High-Risk
atients With Severe Carotid Artery Stenosis
obert D. Safian, MD,* John F. Bresnahan, MD,† Michael R. Jaff, DO,‡ Malcolm Foster, MD,§
. Michael Bacharach, MD, Brijeshwar Maini, MD,¶ Mark Turco, MD,# Subbarao Myla, MD,**
ustav Eles, MD,†† Gary M. Ansel, MD,‡‡ on behalf of the CREATE Pivotal Trial Investigators
oyal Oak, Michigan; Rochester, Minnesota; Nashville, Tennessee; Sioux Falls, South Dakota;
arrisburg and Pittsburgh, Pennsylvania; Washington, DC; Newport Beach, California; and Columbus, Ohio
OBJECTIVES The purpose of this study was to determine the safety of carotid artery stenting with a unique
distal embolic protection system in high-risk patients with severe carotid stenosis.
BACKGROUND Previous studies suggest that some patients with carotid stenosis and serious comorbid
conditions are at high risk for carotid endarterectomy, and may be safely treated by carotid
artery stenting.
METHODS A prospective non-randomized multicenter registry of 419 patients with severe carotid
stenosis and high-risk features for carotid endarterectomy was conducted between April
2004 and October 2004. Carotid artery stenting was performed with the Protégé
Self-Expanding Nitinol Stent and the SPIDER Embolic Protection System (ev3 Inc.,
Plymouth, Minnesota). Aspirin and clopidogrel were prescribed at least 24 h before and
three months after revascularization. The primary outcome was the combined incidence
of major adverse cardiac and cerebrovascular events at 30 days after intervention, including
death, stroke, and myocardial infarction. A secondary outcome was the technical success,
defined as successful deployment of all devices, filter retrieval, and final diameter steno-
sis 50%.
RESULTS Technical success was achieved in 408 of 419 patients (97.4%). The primary end point was
observed in 26 patients (6.2%), including death in 8 (1.9%), nonfatal stroke in 14 (3.3%), and
nonfatal myocardial infarction in 4 (1%). Independent predictors of death or stroke at 30 days
included duration of filter deployment, symptomatic carotid stenosis, and baseline renal
insufficiency.
CONCLUSIONS For some patients with severe carotid stenosis and high-risk features for carotid endarterec-
tomy, carotid artery stenting with distal embolic protection is a reasonable alternative for
revascularization. (J Am Coll Cardiol 2006;47:2384–9) © 2006 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.076of Cardiology Foundation
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carotid artery stenting (CAS) is emerging as a reasonable
herapeutic alternative to carotid endarterectomy (CEA) for
ome patients with severe carotid artery stenosis who are at
igh risk for surgery based on the presence of concomitant
See page 2397
evere cardiovascular, pulmonary, and cerebrovascular dis-
ases (1). Although several studies have evaluated the use of
elf-expanding stents and distal embolic protection systems
n high-risk patients with asymptomatic and symptomatic
From the *William Beaumont Hospital, Royal Oak, Michigan; †Mayo Clinic,
ochester, Minnesota; ‡Cardiovascular Research Foundation, New York, New York;
Baptist Heart Institute, Nashville, Tennessee; North Central Heart Hospital of
outh Dakota, Sioux Falls, South Dakota; ¶Pinnacle Health at Harrisburg Hospital,
arrisburg, Pennsylvania; #Washington Adventist Hospital, Washington, DC;
*Hoag Memorial Hospital, Newport Beach, California; ††Allegheny General Hos-
ital, Pittsburgh, Pennsylvania; and ‡‡Riverside Methodist Hospital, Columbus, Ohio.
his study was funded by an educational research grant from ev3 Inc. (Plymouth,
innesota), which was also responsible for data collection, data analysis, and
anuscript review. The investigators for the CREATE pivotal trial are listed in
ppendix.d
Manuscript received October 18, 2005; revised manuscript received November 29,
005, accepted December 5, 2005.arotid stenosis, the results of these high-risk registries
ave not yet been published. The purpose of this study
as to evaluate the safety of carotid artery revasculariza-
ion using a unique stent and distal embolic protection
ystem.
ETHODS
he Carotid Revascularization with ev3 Arterial Technol-
gy Evolution (CREATE) pivotal trial was approved by the
nstitutional review boards at each of the 32 participating
nstitutions (Appendix), and was in compliance with the
eclaration of Helsinki. Interventional operators were re-
uired to submit a written statement documenting perfor-
ance of at least 30 successful CAS procedures, before
articipation in this study.
tudy design and end points. This study was a prospective
ulticenter registry of CAS in high-risk patients with
evere carotid stenosis. The primary end point of the study
as the composite of major adverse cardiac and cerebrovas-
ular events (MACCE) at 30 days after revascularization,
efined as the occurrence of death, ipsilateral stroke,
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June 20, 2006:2384–9 Carotid Stenting in High-Risk Patientsrocedure-related contralateral stroke, and myocardial infarc-
ion (MI). Strokes were further classified as major or minor
trokes based on the National Institutes of Health Stroke
cale, the Rankin Score, and the Barthel Index (Appendix).
yocardial infarction was defined as any elevation of creatine
inase more than three times the upper limit of normal, and
levation of cardiac isoenzymes, with or without associated
lectrocardiographic changes. The secondary end point was
echnical success, defined as successful deployment and re-
rieval of the distal protection device system, successful stent
eployment, and final diameter stenosis 50%.
atient eligibility and study requirements. The major
ligibility criteria are described in Table 1. Patients with
uspected cervical carotid stenosis generally underwent ca-
otid artery duplex ultrasound evaluation, but criteria for
tenosis severity were defined angiographically. Patients
ho met all general inclusion criteria, one or more high-risk
nclusion criteria (Table 2), and none of the exclusion
riteria (Table 3) were considered for participation in this
Abbreviations and Acronyms
ACAS  Asymptomatic Carotid
Atherosclerosis Study
ACST  Asymptomatic Carotid Surgery Trial
ARCHeR  Acculink for Revascularization of
Carotids in High-Risk Patients trial
CAS  carotid artery stenting
CEA  carotid endarterectomy
CI  confidence interval
CREATE  Carotid Revascularization with ev3
Arterial Technology Evolution trial
ECST  European Carotid Surgery Trial
MACCE  major adverse cardiac and
cerebrovascular events
MI  myocardial infarction
NASCET  North American Symptomatic Carotid
Endarterectomy Trial
OR  odds ratio
SAPPHIRE  Stenting and Angioplasty with Protection
in Patients at High Risk for
Endarterectomy Investigation trial
SECURITY  Registry Study to Evaluate the Neuroshield
Bare Wire Cerebral Protection System and
X-Act Stent in Patients at High Risk for
Carotid Endarterectomy
able 1. Major Eligibility Criteria
tenosis 50%* in common or internal carotid artery
(symptomatic patients)†
tenosis 70%* in common or internal carotid artery
(asymptomatic patients)
arget vessel diameter 4.5 to 9.5 mm for stent
nternal carotid artery diameter 3 to 7 mm for SPIDER device
olerate aspirin, clopidogrel or ticlopidine, and heparin
ge 18 yrs
ust meet high-risk criteria for high-risk patients
ust comply with follow-up and provide informed consent
Stenosis severity was defined using North American Symptomatic Carotid Endar-
erectomy Trial (NASCET) criteria (3); †symptomatic refers to hemispheric transient
schemic attack or stroke within six months of carotid artery stenting.
c
ptudy. Written informed consent was obtained in all pa-
ients according to protocols approved by the institutional
eview boards at each institution. Patients underwent eval-
ation by an independent neurologist or approved surrogate
efore and during intervention, before hospital discharge,
nd at 30 days. Patients with persistent neurological deficits
fter CAS underwent imaging of the brain with computer-
zed tomography or magnetic resonance imaging. All clinical
vents were reviewed and adjudicated by an independent
linical events committee.Methodology for monitoring cardiac
nzymes, blood counts, renal function, and antiplatelet therapy
ave been described previously (2). After CAS, patients were
reated with aspirin (325 mg daily or 81 mg daily if they were
able 2. High-Risk Inclusion Criteria
natomical criteria
Contralateral carotid artery occlusion
Tandem stenoses 70%
High cervical or infraclavicular carotid artery stenosis
Restenosis after carotid endarterectomy
Bilateral carotid artery stenosis requiring treatment
Hostile neck*
linical criteria
Age 75 yrs
2-vessel coronary artery disease and history of angina
Canadian Cardiovascular Society angina class 3 to 4 or unstable angina
New York Heart Association congestive heart failure class 3 to 4
Left ventricular ejection fraction 35%
Myocardial infarction within 6 weeks
Severe pulmonary disease†
Permanent contralateral cranial nerve injury
Defined as prior neck irradiation, radical neck dissection, cervical spine immobility,
racheostomy; †defined as the need for home oxygen, pO2 60 on room air, or forced
xpiratory volume at 1 s 50% predicted.
able 3. Exclusion Criteria
linical criteria
Atrial fibrillation (chronic or paroxysmal) not treated by warfarin
Bleeding requiring blood transfusion within one month of intervention
CABG or vascular surgery within 30 days before or after intervention
Life expectancy 12 months
Intolerance to heparin, aspirin, and both clopidogrel and ticlopidine
No femoral arterial access
MI within 72 h
Prior stent of target carotid artery
Major residual neurological deficit at pre-procedure neurological exam
TIA or amaurosis fugax within 48 h
CVA or retinal embolus within 1 month, with any major
neurological deficit
Allergy to nickel or titanium
Allergy to radiographic contract that cannot be pre-treated
WBC 3,000/mm3, PLT 50,000/mm3 or 700,000/mm3
Intracranial tumor
ngiographic criteria
Target vessel is occluded
Ostium of common carotid artery requires revascularization
Tandem lesions that cannot be covered by one stent
Ipsilateral intracranial stenosis requiring revascularization
Intracranial AVM or aneurysm requiring treatment
VM  arteriovenous malformation; CABG  coronary artery bypass graft surgery;
VA  cerebrovascular accident; MI  myocardial infarction (defined as elevated
reatine kinase more than three times normal and elevated MB fraction); PLT 
latelet count; TIA  transient ischemic attack; WBC  white blood cell count.
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Carotid Stenting in High-Risk Patients June 20, 2006:2384–9aking warfarin, and clopidogrel 75 mg daily) for three months.
etails of the angiographic procedure and deployment of the
PIDER Embolic Protection System and the Protégé GPS
elf-Expanding Nitinol Stent (ev3 Inc., Plymouth Minnesota)
ave been described previously (2). Unlike other distal protec-
ion devices, the Capture Wire in the SPIDER system is not
sed to cross the target lesion. Instead, the operator may select
n independent guidewire to cross the target lesion and access
he distal carotid artery, which may increase the opportunity
or successful crossing.
ata acquisition, study oversight, and statistical methods.
ngiographic and ultrasound data were acquired by inde-
endent core laboratory analyses. All adverse events were
valuated by an independent clinical events committee; were
ategorized as being related to the investigational devices,
he procedure, or not; and were reported to an independent
ata and safety monitoring committee. Data are reported as
ean (SD) for continuous variables and frequency for
ategorical variables. Univariate analysis by logistic regres-
ion (Version 9.1, SAS Institute, Cary, North Carolina) was
erformed on 35 variables to identify correlates of death or
troke within 30 days. Those variables with p  0.20 were
ntered into a multiple logistic regression model to identify
ndependent predictors of outcome, and odds ratios (OR)
or these variables were expressed with 95% confidence
able 4. Baseline Patient Demographic Characteristics
n  419 Patients)
ge (yrs) 73.6  9.1
en:women 61:39
iabetes (%) 31.3
ypertension (%) 90.0
hronic renal failure* (%) 19.1
rior MI (%) 30.1
rior PCI or CABG (%) 52.3
rior TIA or CVA (%) 38.0
rior CEA (%) 29.4
ymptomatic carotid stenosis (%) 17.4
igh-risk criteria (%)
1 criterion 48.2
2 criteria 40.3
3 criteria 11.4
Age 75 yrs 50
Angina class 3 to 4 4
Ejection fraction 35% 10
Multivessel CAD and angina 14
Severe pulmonary disease 4
Hostile neck† 14
CEA restenosis 24
Contralateral occlusion 10
Bilateral carotid stenosis‡ 10
Clinical criteria alone 76.3
Anatomical criteria alone 52.7
Both clinical and anatomic criteria 29.1
Chronic renal failure was defined as baseline serum creatinine 1.5 mg/dl,
ermanent dialysis, or prior renal transplantation; †hostile neck was defined as cervical
carring associated with prior injury due to radiation therapy or surgery, cervical
mmobility, or high carotid stenosis not amenable to CEA; ‡bilateral carotid stenosis
equiring revascularization.
CABG  coronary artery bypass graft surgery; CAD  coronary artery disease;
EA  carotid endarterectomy; CVA  cerebrovascular accident; MI  myocardial(
nfarction; PCI  percutaneous coronary intervention; TIA  transient ischemic
ttack.ntervals (CI). Values of p  0.05 were considered statisti-
ally significant.
ESULTS
atient characteristics and high-risk inclusion criteria.
aseline demographics and high-risk characteristics of the
19 patients are shown in Table 4. High-risk anatomical
riteria were present in 221 (52.7%), high-risk clinical
riteria in 319 (76.3%), and both high-risk anatomical and
linical criteria were present in 122 patients (29.1%). Two or
ore high-risk criteria were present in 217 patients (51.7%).
he three most frequent criteria for inclusion were age 75
ears, multivessel coronary artery disease, and recurrent
tenosis after prior CEA. Baseline angiographic character-
stics are shown in Table 5.
rocedural and 30-day outcomes. Technical success (the
econdary end point of the study) was achieved in 408 of
19 patients (97.4%), and grossly visible debris was observed
n the SPIDER filter in 151 patients (36%) (Tables 6 and
). Technical failure occurred in 11 patients (2.6%), and was
ue to final residual stenosis of 50% to 60% in 2 patients and
ailure to deploy the SPIDER Capture Wire in 9 patients
no intervention was performed in 6 patients and a stent was
eployed without distal protection in 3 patients) due to
natomic limitations such as vessel tortuosity and calcifica-
ion. The primary end point (MACCE) occurred in 26
atients (6.2%), and included death in 8 (1.9%), nonfatal
troke in 14 (3.3%), and MI in 4 (1%; non–ST-segment
levation MI in 3, ST-segment elevation MI in 1). Among
he eight patients who died within 30 days, causes of death
ere fatal stroke in five patients (1.2%), due to intracranial
emorrhage in four and thromboembolic stroke in one; non–
T-segment elevation MI, access site hemorrhage, com-
artment syndrome, and multisystem failure in one; pro-
ressive hypotension and ventricular fibrillation in one; and
evelopment of a femoral artery pseudoaneurysm leading to
ower extremity gangrene and multisystem failure in one
able 5. Baseline Angiographic Results
esion location (%)
Common carotid artery 5.6
Internal carotid artery 75.2
Both 19.1
esion morphology (%)
Eccentric 76.2
Calcified 50.2
Ulcerated 39.1
Thrombus 1.6
Irregular 67.6
uantitative angiography
Proximal vessel diameter (mm) 7.3  2.8
Distal vessel diameter (mm) 5.8  3.7
Vessel diameter at filter site (mm) 5.5  3.6
Lesion length (mm) 17.5  8.9
Diameter stenosis (mm) 82.2  9.0*
After carotid artery stenting, final diameter stenosis was 1.9  18.8%.Table 7).
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June 20, 2006:2384–9 Carotid Stenting in High-Risk PatientsThus, there were a total of 19 strokes (4.5%) within 30
ays of intervention, including fatal major stoke in five
4 hemorrhagic, 1 thromboembolic). The thromboembolic
ajor stroke occurred immediately after a long CAS pro-
edure requiring filter deployment for 50 min, and was
urther complicated by respiratory failure and death within
days (Table 7, Patient #4). All four hemorrhagic strokes
ccurred 4 to 28 days after CAS (Table 7, Patients #5 to
8), including one patient on day 28 after uncomplicated
AS, one patient with possible hyperperfusion syndrome 7
ays after CAS, one patient on warfarin therapy who died 4
ays after CAS despite emergency craniotomy, and one
atient with cerebellar hemorrhage who died 14 days after a
ifficult CAS procedure (filter deployment for 43 min,
ailure to dilate the stent after deployment). Nonfatal stroke
n 14 patients (3.3%) was classified as major stroke in 10
2.3%) and minor stroke in 4 (1%); all patients with minor
troke and 4 patients with major stroke had no residual
isability at 30 days after CAS (Table 7), including 1 patient
ho received intraarterial tissue-type plasminogen activator
mmediately after onset of neurological symptoms. Nonfatal
trokes were due to thromboembolism in 13 patients and
ntracranial hemorrhage in 1 patient who received concom-
tant warfarin for deep venous thrombosis. Among the 10
hromboembolic major strokes (1 fatal, 9 nonfatal), 7
ccurred during complex interventional procedures charac-
erized by one or more of the following features: dissection
f the internal carotid artery requiring multiple stents,
rolonged (30 min) deployment of the SPIDER capture
ire, and technical difficulty retrieving the capture wire.
ntracranial hemorrhage occurred in five patients (1.3%)
ithin 4 to 28 days of CAS, and none were associated with
xcessive procedural anticoagulation. Concomitant warfarin
herapy was administered in two patients, and poorly
able 6. Incidence of Adverse Events at 30 Days
Events n (%)
ny MACCE 26 (6.2)
eath 8 (1.9)
troke* 19 (4.5)
Major 15 (3.5)
Minor 4 (1.0)
Ipsilateral 16 (3.8)
Major 14 (3.3)
Minor 2 (0.5)
Contralateral 3 (0.7)
yocardial infarction 4 (1.0)
ST-segment elevation 1 (0.3)
Non–ST-segment elevation 3 (0.7)
asovagal/vasodepressor reaction 68 (16.2)
ccess site injury 14 (3.3)
astrointestinal bleeding 7 (1.7)
tent thrombosis 0
arget vessel revascularization 0
enal insufficiency 8 (1.9)
See the Appendix for definitions of stroke.
MACCE  major adverse cardiovascular and cerebrovascular events, defined as
eath, stroke, or myocardial infarction within 30 days of intervention.ontrolled hypertension was observed in another patient. tOther non-neurological events included vasovagal or
asodepressor reactions in 68 patients (16.2%), all treated by
dministration of intravenous fluids, atropine, and/or vaso-
ressors; access site complications in 14 patients (3.3%); and
inor gastrointestinal bleeding in 7 patients (1.7%).
redictors of outcome. Thirty-five clinical and anatomical
ariables were analyzed using a logistic regression to deter-
ine their association with death or stroke within 30 days of
AS. Factors associated with adverse outcome by univariate
nalysis included baseline renal insufficiency, symptomatic
arotid stenosis, severe pulmonary disease, lesion calcifica-
ion, absence of an anatomical high-risk feature, and dura-
ion of filter deployment. Whereas there was no difference
n the duration of filter deployment in patients without
troke compared with those with minor stroke (18.8  9.3
in vs. 17.7 7.8 min, pNS), patients with major stroke
ad significantly longer duration of filter deployment com-
ared with patients without stroke (25.7  16.6 min, p 
.004). When divided into four 10-min increments (10
in, 10 to 20 min, 21 to 30 min, 30 min), there was a
ignificant relationship between duration of filter deploy-
ent and the risk of death and stroke (5.1%, 5.0%, 10.3%,
nd 10.8%, respectively; p  0.02). Using a forward step-
ise multivariate analysis, independent predictors of death
nd/or stroke were symptomatic carotid stenosis (OR 2.88,
5% CI 1.2 to 6.8, p  0.015), baseline renal insufficiency
OR 2.92, 95% CI 1.2 to 6.9, p  0.015), and filter
eployment time (p  0.035).
ISCUSSION
he standard of care for symptomatic and asymptomatic
atients with carotid artery stenoses has been established by
he results of four large prospective randomized trials of
edical therapy and CEA (North American Symptomatic
arotid Endarterectomy Trial [NASCET], European
arotid Surgery Trial [ECST], Asymptomatic Carotid
therosclerosis Study [ACAS], and Asymptomatic Ca-
otid Surgery Trial [ACST]) (3–6). These studies sug-
est that patients with symptomatic carotid stenosis 50%
NASCET and ECST) and asymptomatic carotid stenosis
70% (ACAS and ACST) have a significant reduction in
he risk of ipsilateral stroke at five years after CEA com-
ared with patients treated conservatively with aspirin.
owever, CEA is commonly performed in patients who
ould have been excluded from these randomized trials
ecause of advanced age or the presence of serious comorbid
edical conditions (7). In fact, the risk of perioperative
eath and stroke after CEA may be two- to four-fold
igher in high-risk patients with serious cardiopulmonary
isease compared with low-risk patients without such
omorbidity (7).
In a recent randomized trial of CEA and CAS with distal
rotection in high-risk patients (Stenting and Angioplasty
ith Protection in Patients at High Risk for Endarterec-
omy Investigation [SAPPHIRE]) (1), more than half the
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Carotid Stenting in High-Risk Patients June 20, 2006:2384–9atients who were screened were considered too high
isk for CEA, and underwent CAS as part of a high-risk
on-randomized registry. The results of this high-risk
egistry have not yet been published, but these patients have
higher risk profile than those in the randomized trial.
mong high-risk patients who were considered satisfactory
andidates for both revascularization procedures, CAS was
ssociated with a 56% reduction in perioperative death,
troke, and MI compared with CEA, and a 39% reduction
n death and ipsilateral stroke at one year (1). The 6.2% risk
f death, stroke, and MI in our high-risk registry is higher
han the 5.8% risk reported in the SAPPHIRE stent arm,
ut lower than the 7.6% to 8.5% risk in Acculink for
evascularization of Carotids in High-Risk Patients
able 7. Summary of Major Adverse Events at 30 Days After CA
Patient # Age Symptomatic High Risk Event
1 85 Yes Age Death
2 84 Yes Age, EF, CEA Death
3 80 Yes Age, CHF, CEA Death
4 74 Yes HO2 Death
5 67 Yes HO2 Death
6 75 No Age, HO2 CEA  2 Death
7 57 No Angina class 4 Death
8 76 No Age, CEA Death
9 85 No Age MaS
10 67 No EF NSTEM
11 77 No Age, CEA NSTEM
12 60 Yes MVD, CEA STEMI
13 87 No Age MaS
14 74 No Hostile neck, CTO MiS
15 66 Yes Hostile neck MiS
16 77 No Age, CEA MiS
17 80 No Age, MVD MiS
18 66 Yes CEA, CTO, TL MaS
19 83 No Age MaS
20 84 Yes Age MaS
21 84 Yes Age, MVD MaS
22 61 No MVD, angina
class 4
MaS
23 85 No Age MaS
24 82 No Age MaS
25 89 Yes Age MiS
26 88 Yes Age MaS
Symptomatic refers to symptomatic status of patient before carotid artery stenting (C
f the patient before CAS; days refers to the time interval in days between CAS and
orst major event.
CEA restenosis after prior carotid endarterectomy; CHFNew York Heart Ass
rtery; DVT  deep venous thrombosis treated with intravenous heparin; ECG  e
reated by thrombin injection; GIB  gastrointestinal bleeding; Hostile neck  ce
recluding carotid endarterectomy; HO2  severe pulmonary disease requiring home
emorrhage; MaS  major stroke; MiS  minor stroke; MSF  multisystem fail
STEMI  non–ST-segment elevation myocardial infarction; RCA  right corona
achycardia; TL  tandem lesions 70% in the target carotid artery; tPA  intra-art
upport; VF  ventricular fibrillation; VT  ventricular tachycardia.ARCHER) trial (phases 1, 2, and 3) and the 8.5% risk in legistry Study to Evaluate the Neuroshield Bare Wire
erebral Protection System and X-Act Stent in Patients
t High Risk for Carotid Endarterectomy (SECURITY)
8,9). In addition, the risk of periprocedural death and
troke after CAS was 5.2% in our high-risk patients, which
s similar to the 5.6% risk of death and stroke after CEA in
ymptomatic low-risk patients (10), but higher than the 3%
hreshold of perioperative death and stroke established by
he American Heart Association for CEA in asymptomatic
ow-risk patients (11).
Because carotid artery revascularization is most often
ecommended to prevent stroke in asymptomatic patients,
he risk of neurological complications after CAS is partic-
larly important. The 4.5% risk of stroke in this study was
ays Comment
25 FPSA, vascular occlusion, sepsis, MSF
0 VDR, SVT, VT during CAS
17 FPSA, distal embolization to legs, compartment syndrome,
NSTEMI, MSF
2 MaS, respiratory failure during CAS; filter duration 50 min
14 Unable to dilate stent, filter duration 43 min, VF, respiratory
failure during CAS, pneumonia, cerebellar ICH on day 14
28 Massive ICH on day 28
7 Severe HTN, ICH, possible HPPS
4 Filter duration 9 min, ICH after warfarin therapy;
emergency craniotomy
0 Filter duration 15 min, mild disability at 30 days
1 VDR, no ECG changes
2 GIB, no ECG changes
1 Uncomplicated CAS, RCA occlusion treated by stent
26 Multiple stents placed, severe disability at 30 days, stents patent
2 Posterior circulation, no disability at 30 days
0 Difficult SPIDER retrieval, no disability at 30 days
0 Contralateral MiS, no disability at 30 days
0 Contralateral MiS, no disability at 30 days
4 DVT after CAS on warfarin, ICH, moderate disability at
30 days
0 tPA, no disability at 30 days
0 Uncovered dissection distal to stent, no disability at 30 days
1 Distal dissection, multiple stents, filter duration 72 min,
severe disability at 30 days
0 Multiple balloon inflations after stent, filter duration 30 min,
no disability at 30 days
0 Distal dissection, multiple stents, VDR, respiratory failure,
no disability at 30 days
0 Respiratory failure, acute abdomen, sepsis, emergency surgery,
severe disability at 30 days
1 Unable to stent due to lesion calcification and angulation,
no disability at 30 days
0 Difficulty recovering the filter, severe disability at 30 days
egarding transient ischemic attack or stroke; high-risk refers to the high-risk features
ent. For patients with more than one event, the interval refers to the time until the
n class 3 to 4 heart failure; CTO chronic total occlusion of the contralateral carotid
ardiogram; EF  ejection fraction 35%; FPSA  femoral artery pseudoaneurysm
immobility or extensive cervical scarring due to prior radiation therapy or surgery,
en; HPPS  hyperperfusion syndrome; HTN  hypertension; ICH  intracranial
VD  unrevascularized multivessel coronary artery disease and persistent angina;
ry; STEMI  ST-segment elevation myocardial infarction; SVT  supraventricular
issue plasminogen activator; VDR  severe vasodepressor response requiring pressorS*
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June 20, 2006:2384–9 Carotid Stenting in High-Risk Patientsas similar to the 4.4% to 5.5% risk in the ARCHER
tudies (8). The 3.5% risk of major stroke in this study was
lightly higher than the 2.6% risk in the SECURITY trial
nd the 1.1% to 1.4% risk in the ARCHER studies, and
hese differences may be due to differences in clinical or
ngiographic characteristics, differences in the definition of
ajor stroke, or chance. It is unlikely that these differences
re due to the larger pore size of the SPIDER filter, because
he risk of major stroke was 1.9% in the study of the
apid-exchange version of the SPIDER filter (12). Further-
ore, although distal embolic protection devices have been
idely accepted as necessary adjuncts during CAS, failures
ay be due to the inability to deliver the device, device-
nduced complications such as vessel dissection, and incom-
lete capture or retrieval of debris leading to acute stroke;
ll of these complications were observed in this study.
owever, the clustering of strokes after prolonged and
omplex interventional procedures, and the relationship
etween filter deployment duration and stroke, suggests
hat some adverse events may be potentially avoidable by
areful patient selection. Duration of filter deployment
ay be a marker for complex arch and carotid artery
natomy (type C arch, severe carotid artery tortuosity),
ecause these anatomical features often add to procedural
omplexity. Because these features are often found in the
lderly, they may partially explain why advanced age was
eported as a high-risk feature in another registry of low-risk
atients (13).
The observation of intracranial hemorrhage in 1.3% of
atients raises some concern. Concomitant administration
f warfarin and dual antiplatelet therapy may predispose
lderly patients to serious bleeding complications, including
ntracranial hemorrhage. Because similar rates of early
ntracranial hemorrhage have not been reported in coronary
tent patients receiving concomitant warfarin and dual
ntiplatelet therapy, it is possible that hyperperfusion may
lay an incremental role. Further study is needed.
Although neurological complications are the most devas-
ating, the most common complications are vasovagal or
asodepressor responses, possibly due to stretching the
arotid baroreceptor during balloon inflation and stent
eployment. These complications occurred in nearly 20% of
ur patients, and were readily managed with intravenous
uids, atropine, and vasopressors in most patients. How-
ver, patients with poor myocardial reserve due to severe left
entricular dysfunction may be poorly tolerant of hypoten-
ion, so prompt and effective treatment is appropriate.
In conclusion, in some patients with severe carotid
tenosis and high-risk features for CEA, revascularization
ith CAS and distal embolic protection is a safe and
easonable alternative to CEA. In high-risk patients with
enal insufficiency or complex anatomy of the aortic arch tnd carotid artery, in whom prolonged filter deployment
ay be anticipated, the risk of stroke after CAS may be
igher, and the best therapy in these patients is unknown.
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PPENDIX
or a list of the investigating institutions, principal investi-
ators, and number of patients enrolled, as well as the
efinitions of major and minor stroke after CAS, please see
he online version of this article.
